Compounds > arsenic
Page last updated: 2024-08-26

arsenic and Acute Myelogenous Leukemia

arsenic has been researched along with Acute Myelogenous Leukemia in 84 studies

Research

Studies (84)

TimeframeStudies, this research(%)All Research%
pre-19901 (1.19)18.7374
1990's1 (1.19)18.2507
2000's22 (26.19)29.6817
2010's52 (61.90)24.3611
2020's8 (9.52)2.80

Authors

AuthorsStudies
Jia, M; Liu, J; Meng, J; Wang, T; Wen, T; Xu, H; Yang, A; Zhang, X1
Buettner, R; Burnett, J; Ghoda, L; Hoang, DH; Kuo, YH; Marcucci, G; Nguyen, LXT; Pullarkat, V; Rosen, ST; Valerio, M; Zhang, B1
Chen, G; Jiang, H; Li, X; Liu, X; Ma, L; Rouzi, T; She, W; Shen, H; Wang, Q; Wu, J; Yu, C; Zhang, N; Zhou, F1
Fan, T; Guo, XQ; Hu, XM; Li, L; Liu, C; Liu, WY; Lv, Y; Quan, RC; Tang, XD; Wang, HZ; Xiao, HY; Xu, YG1
Cangini, D; Cerchione, C; Ghelli Luserna Di Rorà, A; Giannini, MB; Gottardi, M; Martinelli, G; Padella, A; Simonetti, G; Sperotto, A1
Angelini, DF; Battistini, L; Berardi, A; Castelli, G; Catalano, G; Cicconi, L; D'Angiò, A; Fioritoni, G; Graziani, G; Guerrera, G; Lo-Coco, F; Massai, L; Mastrangelo, D; Noguera, NI; Pasquini, L; Pelosi, E; Piras, E; Piredda, ML; Testa, U; Voso, MT1
Chahardouli, B; Ghavamzadeh, A; Mohammadi Kian, M; Mohammadi, S; Nikbakht, M; Rostami, S; Tavallaei, M; Zahedpanah, M1
Ding, SM; Kan, JY; Wang, Y; Xu, RR1
Chen, L; Han, F; Qu, H; Ren, L; Yan, H; Yang, S1
Baumann, H; Brady, MT; Ford, LA; Lee, KP; Miller, A; Minderman, H; Sait, SN; Wang, ES; Wetzler, M1
Bae, JY; Kim, I; Kim, JW1
Fan, RH; Mi, RH; Song, YP; Wei, XD; Xu, JX; Yin, QS1
Cen, JN; Fu, CM; Hu, SY; Jiao, Y; Li, Z; Qi, XF; Qiu, HY; Wu, DP; Zhu, MQ1
Chan, SM; Feng, W; Huang, M; Li, MX; Majeti, R; Mitchell, BS; Thomas, D1
Mehta, SV; Shukla, SN; Vora, HH1
Dent, P1
Hirano, T; Hu, XM; Onda, K; Song, MM; Tanaka, S; Tohyama, K; Toyoda, H; Yuan, B; Zhou, AX1
Fujii, Y; Komatsu, T; Shigemi, H; Tanaka, Y; Yamauchi, T1
Altman, JK; Beauchamp, E; Eklund, EA; Goussetis, DJ; Kosciuczuk, EM; Platanias, LC; Wu, EJ1
Aldoss, I; Douer, D; Mark, L; Mohrbacher, AM; Ramezani, L; Vrona, J; Weitz, I1
Bi, L; Jiang, L; Lin, F; Ni, W; Tan, Y; Wang, F; Wu, J; Zhang, P1
Altman, JK; Beauchamp, EM; Kosciuczuk, EM; Nanavati, D; O'Halloran, TV; Platanias, LC; Serrano, R; Swindell, EP; Viollet, B1
Chen, X; Dong, K; He, T; Li, J; Lin, F; Long, M; Ouyang, Y; Wang, X; Wei, J; Weng, Y; Zhang, H1
Aller, P; Boyano-Adánez, Mdel C; Calviño, E; Calvo, S; de Blas, E; Estañ, MC; Guillén-Guío, B; Rial, E1
Bai, X; Guo, K; Guo, Z; He, H; He, X; Qiu, D; Wang, J; Weng, G; Xu, X; Ye, Y; Yi, W; Zhang, M; Zhou, R1
Banfic, H; Dembitz, V; Lalic, H; Ostojic, A; Visnjic, D; Vrhovac, R1
Brunetti, L; Di Raimondo, F; Falini, B; Gionfriddo, I; Martelli, MP; Mezzasoma, F; Milano, F; Mulas, F; Pacini, R; Pettirossi, V; Pierangeli, S; Rossi, R; Sportoletti, P; Tabarrini, A; Tiacci, E; Vetro, C1
Ades, L; Bazarbachi, A; Berthier, C; Darwiche, N; Dassouki, Z; de Thé, H; Dombret, H; El Hajj, H; Fenaux, P; Hleihel, R; Legrand, O; Mohty, M; Raffoux, E; Sahin, U; Salameh, A; Tawil, N; Zibara, K1
Chan, TS; Chau, D; Cheng, YY; Fong, B; Kwong, YL; Ng, K; Tam, S; Tse, E1
Bhatnagar, V; Carter-Cooper, B; Emadi, A; Lapidus, RG; Levis, MJ; Sadowska, M; Sausville, EA; van der Merwe, I1
Grant, S1
Chen, Z; Chen, ZZ; Jiang, JP; Li, J; Lin, SY; Qian, WB; Shen, YY; Wang, B; Wu, LQ1
Gu, H; Li, L; Ren, Y; Zhang, H; Zhang, L1
Kolb, EA; Meshinchi, S1
Guo, H; Li, X; Liu, J; Ma, Q; Meng, J; Wang, C; Xu, H1
Ashton, JM; Becker, MW; Gasparetto, M; Humphries, KR; Jordan, CT; Khan, N; Minhajuddin, M; Myers, JR; Pei, S; Pollyea, DA; Smith, CA; Vasiliou, V1
Roboz, GJ1
Chen, KS; Chou, MC; Chu, SC; Hsiao, YC; Hsieh, YS; Kuo, DY; Lin, TH1
Allen-Bard, S; Carlin, R; Christos, PJ; Curcio, T; Feldman, EJ; Mathew, S; Mazumdar, M; Provenzano, J; Ritchie, EK; Roboz, GJ; Samuel, M; Wittenberg, B1
Au, WY; Fong, BM; Kwong, YL; Tam, S1
Coe, E; Schimmer, AD1
Haferlach, T1
Chen, YW; Freireich, E; Kantarjian, H; Quintás-Cardama, A; Verstovsek, S; Zingaro, R1
Petrie, K; Waxman, S; Zelent, A1
Dong, D; Fei, J; Gu, J; Hu, H; Huang, K; Li, Y; Lin, C; Yao, J; Zhu, X1
Canestraro, M; Cine, N; Galimberti, S; Guerrini, F; Metelli, MR; Nagy, B; Palumbo, GA; Petrini, M; Piaggi, S; Savli, H; Tibullo, D1
Altman, JK; Glaser, H; Goussetis, DJ; McNeer, JL; Platanias, LC; Tallman, MS1
Advani, A; Afable, M; Chan, J; Englehaupt, R; Erba, HP; Kalaycio, ME; Maciejewski, JP; Seel, S; Sekeres, MA; Sobecks, R1
Andrews, C; Baer, MR; Barcos, M; Baumann, H; Block, AW; Ford, LA; Nowak, NJ; Sait, SN; Tighe, S; Wang, ES; Wetzler, M1
Bowen, D; Burnett, AK; Cahalin, P; Craig, J; Hills, RK; Hunter, A; Kell, J; McMullin, MF; Milligan, D; Russell, N; Wheatley, K; Yin, J1
Burnett, AK; Hills, RK1
Bechelli, J; Ifthikharuddin, JJ; Jordan, CT; Liesveld, JL; Lu, C; Messina, P; Mulford, D; Phillips Ii, GL; Rosell, KE1
Cao, Y; Gong, Q; Han, Z; Hong, Z; Li, C; Ma, D; Meng, L; Wu, Y; Xiao, M; Xu, D; Yang, Y; Zhou, J; Zhou, X1
Abboud, CN; Cashen, AF; DiPersio, JF; Gao, F; Hassan, A; Klco, JM; Procknow, E; Stockerl-Goldstein, KE; Uy, GL; Vij, R; Welch, JS; Westervelt, P1
Cao, L; Liu, L; Wang, Z; Xie, M; Yang, L; Yang, M; Yu, Y; Zhang, H; Zhao, M1
Batár, P; Kiss, A; Rejto, L; Reményi, G; Szász, R; Telek, B; Udvardy, M; Ujj, ZÁ1
Christos, PJ; Feldman, EJ; Gergis, U; Mayer, S; Ritchie, EK; Roboz, GJ; Scandura, JM; Wissa, U1
Ding, Y; Fei, J; Li, Y; Zhang, Y; Zhu, X1
Gabrilove, J; Jing, Y; Wang, R; Waxman, S; Xia, L1
Chen, XL; Cong, WH; Guo, G; Li, H; Li, XX; Wang, R; Yu, XN1
Chen, H; Liu, J; Liu, L; Liu, M; Shi, B; Ye, L; Yu, L; Zhang, Y1
Altman, JK; Galvin, JP; Goussetis, DJ; Platanias, LC; Sassano, A; Szilard, A; Vakana, E1
Udvardy, M1
Takeshita, A1
Meng, R; Yang, BF; Zhao, DY; Zhou, J1
Hahm, ER; Han, SS; Jung, CW; Kim, K; Kim, WS; Kimler, BF; Lee, JH; Lee, MH; Lee, SJ; Park, CH; Park, HK; Park, K; Park, S; Riordan, HD; Riordan, NH; Surh, YJ; Yang, JH; Yoon, SS1
Hahm, ER; Han, SS; Jung, CW; Kim, J; Kim, K; Kim, WS; Kimler, BF; Lee, JH; Lee, SH; Lee, SJ; Park, CH; Park, K; Park, S; Yoon, SS1
Civallero, M; Cosenza, M; Marcheselli, R; Pozzi, S; Sacchi, S1
Bonati, A; Costanzo, A; Levrero, M; Lo-Coco, F; Lunghi, P; Mazzera, L; Noguera, N; Salvatore, L; Tabilio, A1
Meng, L; Meng, R; Sui, XH; Yang, BF; Zhou, J1
Abe, S; Harigae, H; Imaizumi, M; Ishikawa, I; Kaku, M; Sasaki, T; Takahashi, S; Yokoyama, H1
Baer, MR; Baumann, H; Brady, MT; Cheng, Y; Cowell, JK; Donohue, KA; Kunapuli, P; Li, ZR; McDonald, AA; Mortazavi, A; O'Loughlin, KL; Tracy, E; Wallace, PK; Wetzler, M1
Chen, FY; Han, JY; Huang, HH; Wang, HR; Zhong, H; Zhong, JH; Zhu, JY1
Altman, JK; Glaser, H; Hay, N; Jordan, A; Katsoulidis, E; Kroczynska, B; Platanias, LC; Redig, AJ; Sassano, A; Tallman, MS; Yoon, P1
Craig, CM; Schiller, GJ1
Ayzac, L; Bergeret, A; Bonhomme, I; Dananche, B; Fabry, J; Fevotte, J; Fière, D; Hours, M; Milan, JJ; Philippe, J1
Bengtzen, S; Christensson, B; Lehmann, S; Paul, A; Paul, C1
Chen, Z; Hu, XM; Liu, C; Liu, WY; Lyu, Y; Quan, RC; Tang, XD; Wu, YH; Xiao, HY1
Jin, J; Naranmandura, H; Qian, JJ; Sun, WJ; Wang, QQ; You, LS; Zhu, HH1
de Thé, H; Esnault, C; Rahmé, R1
Balleari, E; Bernal, T; Beyne-Rauzy, O; Bordessoule, D; Calabuig, M; Cametti, G; Campelo, MD; Cheze, S; Cony-Makhoul, P; Dreyfus, F; Fenaux, P; Fensterl, J; Ferrero, D; Gaidano, G; Germing, U; Gioia, D; Götze, K; Guerci-Bresler, A; Hamel, JF; Kaivers, J; Kelaidi, C; Komrokji, R; Kotsianidis, I; Müller-Thomas, C; Pane, F; Park, S; Ramos, F; Roboz, GJ; Rose, C; Sanna, A; Santini, V; Sanz, GF; Sapena, R; Sekeres, MA; Stamatoullas, A; Steensma, DP; Thépot, S; Toma, A; Vey, N; Wattel, E1
Levis, M1
Cockburn, M; Heck, JE; Park, AS; Qiu, J; Ritz, B1
Kjeldsberg, CR; Ward, HP1

Reviews

9 review(s) available for arsenic and Acute Myelogenous Leukemia

ArticleYear
Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and future.
    Minerva medica, 2020, Volume: 111, Issue:5

    Topics: Aged; Animals; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Arsenicals; Calicheamicins; Chlorides; Clinical Trials as Topic; Cytarabine; Daunorubicin; Drug Approval; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Mice; Middle Aged; Multicenter Studies as Topic; Recurrence; Sialic Acid Binding Ig-like Lectin 3; Tretinoin

2020
Acute myeloid leukemia in children and adolescents: identification of new molecular targets brings promise of new therapies.
    Hematology. American Society of Hematology. Education Program, 2015, Volume: 2015

    Topics: Adolescent; Adult; Arsenic Trioxide; Arsenicals; Child; Child, Preschool; Clinical Trials as Topic; Down Syndrome; Epigenesis, Genetic; GATA1 Transcription Factor; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Medical Oncology; Molecular Medicine; Mutation; Oxides; ras Proteins; Receptor Protein-Tyrosine Kinases; Treatment Outcome; Tretinoin

2015
Arsenic and old lace: novel approaches in elderly patients with acute myeloid leukemia.
    Seminars in hematology, 2008, Volume: 45, Issue:3 Suppl 2

    Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Oxides; Treatment Outcome

2008
Molecular genetic pathways as therapeutic targets in acute myeloid leukemia.
    Hematology. American Society of Hematology. Education Program, 2008

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Division; Chromosome Aberrations; Genetic Markers; Humans; Karyotyping; Leukemia, Myeloid, Acute; Models, Genetic; Mutation; Oxides; Proto-Oncogene Proteins c-kit; Transcription, Genetic; Tretinoin

2008
Differentiation therapy of acute myeloid leukemia: past, present and future.
    Current opinion in hematology, 2009, Volume: 16, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Myeloid, Acute; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Sensitivity and Specificity; Tretinoin

2009
[Current treatment of acute myeloid leukaemia in adults].
    Orvosi hetilap, 2012, Feb-19, Volume: 153, Issue:7

    Topics: Age Factors; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mitoxantrone; Molecular Targeted Therapy; Oxides; Prognosis; Pyrazines; Recurrence; Transplantation, Homologous; Treatment Outcome; Tretinoin

2012
[Expanding possibilities, strategic considerations, and novel methods in the diagnosis and chemotherapy of adult acute myeloid leukemia].
    Orvosi hetilap, 2003, Sep-07, Volume: 144, Issue:36

    Topics: Adult; Anthracyclines; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Oligonucleotide Array Sequence Analysis; Oxides; Palliative Care; Prognosis; Remission Induction; Tretinoin

2003
[Recent advances in the treatment of acute myelogenous leukemia: a view of the new agents].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2003, Volume: 44, Issue:12

    Topics: Alkyl and Aryl Transferases; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzoates; Cyclosporine; Cytarabine; Daunorubicin; Drug Design; Farnesyltranstransferase; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Nucleosides; Oxides; Prognosis; Radioisotopes; Remission Induction; Tetrahydronaphthalenes; Topoisomerase Inhibitors; Tretinoin; Verapamil

2003
Acute myeloid leukemia in the elderly: conventional and novel treatment approaches.
    Blood reviews, 2008, Volume: 22, Issue:4

    Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Arabinonucleosides; Arsenic Trioxide; Arsenicals; Azacitidine; Clofarabine; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Oxides; Recurrence; Sulfonamides

2008

Trials

9 trial(s) available for arsenic and Acute Myelogenous Leukemia

ArticleYear
Adding ascorbic acid to arsenic trioxide produces limited benefit in patients with acute myeloid leukemia excluding acute promyelocytic leukemia.
    Annals of hematology, 2014, Volume: 93, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Oxides; Treatment Outcome

2014
Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia.
    Cancer, 2008, Nov-01, Volume: 113, Issue:9

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Oxides; Prognosis; Remission Induction; Survival Rate

2008
A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia.
    Cancer, 2011, Mar-15, Volume: 117, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Administration Schedule; Female; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Oxides; Salvage Therapy; Treatment Outcome

2011
Phase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to down-regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemia.
    Cancer, 2011, Nov-01, Volume: 117, Issue:21

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Down-Regulation; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Oxides; STAT3 Transcription Factor

2011
The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome.
    Leukemia, 2011, Volume: 25, Issue:7

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Chemical and Drug Induced Liver Injury; Comorbidity; Cytarabine; Disease-Free Survival; Early Termination of Clinical Trials; Female; Gastrointestinal Diseases; Heart Diseases; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Oxides; Remission Induction; Treatment Outcome

2011
Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines.
    Cancer investigation, 2011, Volume: 29, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Benzenesulfonates; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cytarabine; Cytokines; Farnesyltranstransferase; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Niacinamide; Oxides; Phenylurea Compounds; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyridines; Sorafenib

2011
Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study.
    American journal of hematology, 2011, Volume: 86, Issue:9

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Azacitidine; Bone Marrow; Bone Marrow Cells; Cohort Studies; Decitabine; Dose-Response Relationship, Drug; Female; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Young Adult

2011
Effects of arsenic trioxide administration styles on leukocytosis.
    Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih, 2006, Volume: 21, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Humans; Infusions, Intravenous; K562 Cells; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Leukocytosis; Oxides

2006
Synergistic effect of arsenic trioxide and flt3 inhibition on cells with flt3 internal tandem duplication.
    International journal of hematology, 2006, Volume: 84, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Dose-Response Relationship, Drug; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mitogen-Activated Protein Kinase Kinases; Mutation; Oxides; Signal Transduction; Tumor Cells, Cultured; Tyrphostins

2006

Other Studies

66 other study(ies) available for arsenic and Acute Myelogenous Leukemia

ArticleYear
Hydrophilic Realgar Nanocrystals Prolong the Survival of Refractory Acute Myeloid Leukemia Mice Through Inducing Multi-Lineage Differentiation and Apoptosis.
    International journal of nanomedicine, 2022, Volume: 17

    Topics: Animals; Apoptosis; Arsenicals; Cell Differentiation; Leukemia, Myeloid, Acute; Mice; Nanoparticles; Sulfides

2022
Arsenic Trioxide and Venetoclax Synergize against AML Progenitors by ROS Induction and Inhibition of Nrf2 Activation.
    International journal of molecular sciences, 2022, Jun-12, Volume: 23, Issue:12

    Topics: Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Bridged Bicyclo Compounds, Heterocyclic; Humans; Leukemia, Myeloid, Acute; NF-E2-Related Factor 2; Oxides; Reactive Oxygen Species; Recurrence; Sulfonamides

2022
A novel organic arsenic derivative MZ2 remodels metabolism and triggers mtROS-mediated apoptosis in acute myeloid leukemia.
    Journal of cancer research and clinical oncology, 2023, Volume: 149, Issue:8

    Topics: Animals; Apoptosis; Arsenic; Arsenicals; Cell Line, Tumor; Cell Proliferation; Humans; Leukemia, Myeloid, Acute; Mice

2023
Arsenic-Containing Qinghuang Powder () is an Alternative Treatment for Elderly Acute Myeloid Leukemia Patients Refusing Low-Intensity Chemotherapy.
    Chinese journal of integrative medicine, 2020, Volume: 26, Issue:5

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Arsenicals; Drugs, Chinese Herbal; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Powders; Retrospective Studies

2020
High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro.
    Oncotarget, 2017, May-16, Volume: 8, Issue:20

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Oxides; Reactive Oxygen Species; Survival Analysis; Tumor Cells, Cultured

2017
Inhibitory Effects of Arsenic Trioxide and Thalidomide on Angiogenesis and Vascular Endothelial Growth Factor Expression in Leukemia Cells
    Asian Pacific journal of cancer prevention : APJCP, 2018, Apr-27, Volume: 19, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Humans; Leukemia, Myeloid, Acute; Neovascularization, Pathologic; Oxides; Thalidomide; U937 Cells; Vascular Endothelial Growth Factors

2018
[Effects of Arsenic Trioxide on Cdc20 and Mad2 in Acute Myeloid Leukemia HL-60 Cell Line].
    Zhongguo shi yan xue ye xue za zhi, 2018, Volume: 26, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cdc20 Proteins; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Oxides

2018
Combination therapy with 5-amino-4-imidazolecarboxamide riboside and arsenic trioxide in acute myeloid leukemia cells involving AMPK/TSC2/mTOR pathway.
    Die Pharmazie, 2013, Volume: 68, Issue:2

    Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; HL-60 Cells; Humans; Hypoglycemic Agents; Leukemia, Myeloid, Acute; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; Ribonucleotides; Signal Transduction; TOR Serine-Threonine Kinases; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins

2013
Down-regulation of signal transducer and activator of transcription 3 improves human acute myeloid leukemia-derived dendritic cell function.
    Leukemia research, 2013, Volume: 37, Issue:7

    Topics: Aminosalicylic Acids; Antigen-Presenting Cells; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzenesulfonates; Blast Crisis; Blotting, Western; Dendritic Cells; Down-Regulation; Endocytosis; Enzyme-Linked Immunosorbent Assay; Humans; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Lymphocyte Activation; Oxides; RNA, Small Interfering; Signal Transduction; STAT3 Transcription Factor; T-Lymphocytes; Tumor Cells, Cultured

2013
Low-dose 1,25-dihydroxyvitamin D(3) combined with arsenic trioxide synergistically inhibits proliferation of acute myeloid leukemia cells by promoting apoptosis.
    Oncology reports, 2013, Volume: 30, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Bone Density Conservation Agents; Calcitriol; Caspase 3; Cell Line, Tumor; Cell Survival; Glyceraldehyde 3-Phosphate Dehydrogenase (NADP+); HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid, Acute; Oxides; Proto-Oncogene Proteins c-bcl-2

2013
[Effect of TAK1 gene silencing on the apoptosis of Kasumi-1 cells induced by arsenic trioxide].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2013, Volume: 34, Issue:5

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Humans; JNK Mitogen-Activated Protein Kinases; Leukemia, Myeloid, Acute; MAP Kinase Kinase Kinases; Oxides; RNA Interference; RNA, Small Interfering; Signal Transduction

2013
Growth and differentiation effects of Homer3 on a leukemia cell line.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Carrier Proteins; Cell Cycle; Cell Differentiation; Cell Proliferation; Flow Cytometry; Gene Expression Regulation, Neoplastic; Homer Scaffolding Proteins; Humans; Leukemia, Myeloid, Acute; Oxides; Proto-Oncogene Proteins c-bcl-2; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured

2013
Role of cysteine 288 in nucleophosmin cytoplasmic mutations: sensitization to toxicity induced by arsenic trioxide and bortezomib.
    Leukemia, 2013, Volume: 27, Issue:10

    Topics: Acetylcysteine; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Nucleolus; Cell Proliferation; Cysteine; Cytosol; Drug Resistance, Neoplasm; Flow Cytometry; Free Radical Scavengers; Humans; Leukemia, Myeloid, Acute; Mutation; Nuclear Proteins; Nucleophosmin; Oxides; Pyrazines; Reactive Oxygen Species; Tryptophan; Tumor Cells, Cultured

2013
Overexpression of Bcl2 protein predicts chemoresistance in acute myeloid leukemia: its correlation with FLT3.
    Neoplasma, 2013, Volume: 60, Issue:6

    Topics: Adolescent; Adult; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Drug Resistance, Neoplasm; Female; Flow Cytometry; fms-Like Tyrosine Kinase 3; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Oxides; Prognosis; Proto-Oncogene Proteins c-bcl-2; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tandem Repeat Sequences; Tretinoin; Young Adult

2013
Arsenic in leukemia: a RSKy business.
    Cancer biology & therapy, 2013, Oct-01, Volume: 14, Issue:10

    Topics: Arsenicals; Humans; Leukemia, Myeloid, Acute; Oxides; Ribosomal Protein S6 Kinases, 90-kDa

2013
Arsenic disulfide-triggered apoptosis and erythroid differentiation in myelodysplastic syndrome and acute myeloid leukemia cell lines.
    Hematology (Amsterdam, Netherlands), 2014, Volume: 19, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Arsenicals; Cell Differentiation; Cell Proliferation; Erythroid Cells; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; p38 Mitogen-Activated Protein Kinases; Sulfides

2014
BIMEL is a key effector molecule in oxidative stress-mediated apoptosis in acute myeloid leukemia cells when combined with arsenic trioxide and buthionine sulfoximine.
    BMC cancer, 2014, Jan-15, Volume: 14

    Topics: Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Bcl-2-Like Protein 11; Buthionine Sulfoximine; Drug Combinations; Gene Knockdown Techniques; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Membrane Proteins; Oxidative Stress; Oxides; Phosphorylation; Proto-Oncogene Proteins

2014
Resveratrol enhances the suppressive effects of arsenic trioxide on primitive leukemic progenitors.
    Cancer biology & therapy, 2014, Volume: 15, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Cell Line, Tumor; Drug Synergism; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Oxides; Resveratrol; Stilbenes

2014
Thioredoxin-1 inhibitor PX-12 induces human acute myeloid leukemia cell apoptosis and enhances the sensitivity of cells to arsenic trioxide.
    International journal of clinical and experimental pathology, 2014, Volume: 7, Issue:8

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Line, Tumor; Cell Survival; Disulfides; Flow Cytometry; HL-60 Cells; Humans; Imidazoles; Leukemia, Myeloid, Acute; Oxides; Thioredoxins

2014
Direct binding of arsenic trioxide to AMPK and generation of inhibitory effects on acute myeloid leukemia precursors.
    Molecular cancer therapeutics, 2015, Volume: 14, Issue:1

    Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Humans; Leukemia, Myeloid, Acute; Mice; Oxides; Ribosomal Protein S6 Kinases, 90-kDa; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2015
Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia.
    Cellular signalling, 2015, Volume: 27, Issue:3

    Topics: Aged; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; B7-H1 Antigen; Base Sequence; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Interferon-gamma; Leukemia, Myeloid, Acute; Male; MicroRNAs; Middle Aged; Oligonucleotides, Antisense; Oxides; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Sequence Alignment; Up-Regulation

2015
Apoptotic efficacy of etomoxir in human acute myeloid leukemia cells. Cooperation with arsenic trioxide and glycolytic inhibitors, and regulation by oxidative stress and protein kinase activities.
    PloS one, 2014, Volume: 9, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Deoxyglucose; Epoxy Compounds; Glycolysis; Humans; Indazoles; Leukemia, Myeloid, Acute; Oxidative Stress; Oxides; Protein Kinases

2014
Low-dose arsenic trioxide combined with aclacinomycin A synergistically enhances the cytotoxic effect on human acute myelogenous leukemia cell lines by induction of apoptosis.
    Leukemia & lymphoma, 2015, Volume: 56, Issue:11

    Topics: Aclarubicin; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Oxides

2015
The mechanism of synergistic effects of arsenic trioxide and rapamycin in acute myeloid leukemia cell lines lacking typical t(15;17) translocation.
    International journal of hematology, 2015, Volume: 102, Issue:1

    Topics: Aged; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Line, Tumor; Cell Survival; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Drug Synergism; Female; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitogen-Activated Protein Kinases; Oxides; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Translocation, Genetic

2015
Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells.
    Blood, 2015, May-28, Volume: 125, Issue:22

    Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Myeloid, Acute; Mice; Mice, SCID; Mutant Proteins; Mutation; Nuclear Proteins; Nucleophosmin; Oncogene Proteins; Oxides; Tretinoin; Tumor Cells, Cultured; U937 Cells; Xenograft Model Antitumor Assays

2015
Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells.
    Blood, 2015, May-28, Volume: 125, Issue:22

    Topics: Aged; Aged, 80 and over; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Humans; Leukemia, Myeloid, Acute; Mutant Proteins; Mutation; Nuclear Proteins; Nucleophosmin; Oxides; Proteolysis; Tretinoin; Tumor Cells, Cultured

2015
Azacytidine sensitizes acute myeloid leukemia cells to arsenic trioxide by up-regulating the arsenic transporter aquaglyceroporin 9.
    Journal of hematology & oncology, 2015, May-08, Volume: 8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Aquaporins; Arsenic Trioxide; Arsenicals; Azacitidine; Blotting, Western; Cell Line, Tumor; Cells, Cultured; Drug Synergism; Flow Cytometry; Humans; Leukemia, Myeloid, Acute; Oxides; Polymerase Chain Reaction; RNA, Small Interfering; Transfection; Up-Regulation

2015
Perturbation of cellular oxidative state induced by dichloroacetate and arsenic trioxide for treatment of acute myeloid leukemia.
    Leukemia research, 2015, Volume: 39, Issue:7

    Topics: Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Dichloroacetic Acid; Humans; Leukemia, Myeloid, Acute; Oxidative Stress; Oxides

2015
ATRA and ATO team up against NPM1.
    Blood, 2015, May-28, Volume: 125, Issue:22

    Topics: Animals; Apoptosis; Arsenicals; Humans; Leukemia, Myeloid, Acute; Nuclear Proteins; Nucleophosmin; Oxides; Proteolysis; Tretinoin

2015
Pure total flavonoids from Citrus paradisi Macfadyen act synergistically with arsenic trioxide in inducing apoptosis of Kasumi-1 leukemia cells in vitro.
    Journal of Zhejiang University. Science. B, 2015, Volume: 16, Issue:7

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Flavonoids; Humans; Leukemia, Myeloid, Acute; Oxides; Plant Extracts; Treatment Outcome

2015
EZH2 mediates ATO-induced apoptosis in acute myeloid leukemia cell lines through the Wnt signaling pathway.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Gene Expression; Gene Knockdown Techniques; Glycogen Synthase Kinase 3 beta; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Oxides; Phosphorylation; Wnt Signaling Pathway

2016
Fabrication of water-soluble polymer-encapsulated As4S4 to increase oral bioavailability and chemotherapeutic efficacy in AML mice.
    Scientific reports, 2016, 07-07, Volume: 6

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Arsenicals; Biological Availability; Disease Models, Animal; Female; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Liver; Male; Mice; Microscopy, Electron, Scanning; Polymers; Rats; Rats, Sprague-Dawley; Solubility; Spleen; Sulfides; Survival Analysis; Water

2016
Targeted therapy for a subset of acute myeloid leukemias that lack expression of aldehyde dehydrogenase 1A1.
    Haematologica, 2017, Volume: 102, Issue:6

    Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Arsenic Trioxide; Arsenicals; Cells, Cultured; Cyclophosphamide; Drug Therapy, Combination; Heterografts; Humans; Leukemia, Myeloid, Acute; Mice; Molecular Targeted Therapy; Oxides; Retinal Dehydrogenase

2017
Tannic acid-induced apoptosis and -enhanced sensitivity to arsenic trioxide in human leukemia HL-60 cells.
    Leukemia research, 2009, Volume: 33, Issue:2

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Dose-Response Relationship, Drug; Drug Synergism; HL-60 Cells; Humans; Kinetics; Leukemia, Myeloid, Acute; Mitochondria; Oxides; Superoxide Dismutase; Tannins

2009
Oral arsenic treatment of leukemia and the risk of porphyria.
    Leukemia research, 2009, Volume: 33, Issue:4

    Topics: Administration, Oral; Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Male; Oxides; Porphyrias; Porphyrins

2009
Catalase activity and arsenic sensitivity in acute leukemia.
    Leukemia & lymphoma, 2008, Volume: 49, Issue:10

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Catalase; Cell Line, Tumor; Enzyme Inhibitors; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Oxides; Tumor Cells, Cultured

2008
Chemical and clinical development of darinaparsin, a novel organic arsenic derivative.
    Anti-cancer agents in medicinal chemistry, 2008, Volume: 8, Issue:8

    Topics: Animals; Antineoplastic Agents; Arsenicals; Drug Screening Assays, Antitumor; Glutathione; Humans; Leukemia, Myeloid, Acute; Mice

2008
miRNA-21 regulates arsenic-induced anti-leukemia activity in myelogenous cell lines.
    Medical oncology (Northwood, London, England), 2011, Volume: 28, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Blotting, Western; Cell Cycle; Cell Proliferation; Flow Cytometry; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; MicroRNAs; Oxides; Reverse Transcriptase Polymerase Chain Reaction; RNA-Binding Proteins; RNA, Messenger; Tumor Cells, Cultured

2011
Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders.
    Cancer genetics and cytogenetics, 2010, Volume: 199, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Biomarkers, Tumor; Blast Crisis; Blotting, Western; Boronic Acids; Bortezomib; Caspase 8; Cell Cycle; Cell Proliferation; Drug Synergism; Gene Expression Profiling; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Myeloproliferative Disorders; NF-kappa B; Oligonucleotide Array Sequence Analysis; Oxides; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Reactive Oxygen Species; Receptors, TNF-Related Apoptosis-Inducing Ligand; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; TNF-Related Apoptosis-Inducing Ligand

2010
Autophagy is a critical mechanism for the induction of the antileukemic effects of arsenic trioxide.
    The Journal of biological chemistry, 2010, Sep-24, Volume: 285, Issue:39

    Topics: Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Autophagy; Autophagy-Related Protein 7; Beclin-1; Humans; Leukemia, Myeloid, Acute; MAP Kinase Signaling System; Membrane Proteins; Mice; Mice, Knockout; Microtubule-Associated Proteins; Oxides; U937 Cells; Ubiquitin-Activating Enzymes

2010
Applicability of a "Pick a Winner" trial design to acute myeloid leukemia.
    Blood, 2011, Sep-01, Volume: 118, Issue:9

    Topics: Adenine Nucleotides; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Arsenic Trioxide; Arsenicals; Clinical Trials, Phase III as Topic; Clofarabine; Cost-Benefit Analysis; Cytarabine; Cytosine; Drug Discovery; Early Termination of Clinical Trials; Follow-Up Studies; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Middle Aged; Multicenter Studies as Topic; Oxides; Patient Selection; Quality-Adjusted Life Years; Quinolones; Randomized Controlled Trials as Topic; Research Design; Sample Size; Software Design; Treatment Outcome; United Kingdom

2011
Arsenic disulfide synergizes with the phosphoinositide 3-kinase inhibitor PI-103 to eradicate acute myeloid leukemia stem cells by inducing differentiation.
    Carcinogenesis, 2011, Volume: 32, Issue:10

    Topics: Animals; Apoptosis; Arsenicals; Blotting, Western; Cell Differentiation; Cell Line, Tumor; Drug Synergism; Furans; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Pyrimidines; Sulfides; TOR Serine-Threonine Kinases

2011
S100A8-targeting siRNA enhances arsenic trioxide-induced myeloid leukemia cell death by down-regulating autophagy.
    International journal of molecular medicine, 2012, Volume: 29, Issue:1

    Topics: Active Transport, Cell Nucleus; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Autophagy; Beclin-1; Calgranulin A; Down-Regulation; Drug Synergism; Flow Cytometry; HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid, Acute; Membrane Proteins; Oxides; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; RNA, Small Interfering; Transfection; Tumor Cells, Cultured

2012
Are low-intensity induction strategies better for older patients with acute myeloid leukemia?
    Leukemia research, 2012, Volume: 36, Issue:4

    Topics: Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cytarabine; Daunorubicin; Etoposide; Female; Gemtuzumab; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Oxides; Quinolones; Remission Induction; Retrospective Studies; Treatment Outcome

2012
Targeted inhibition of VEGF-modulated survival and arsenic sensitivity in acute myeloid leukemia (AML).
    Hematology (Amsterdam, Netherlands), 2012, Volume: 17, Issue:3

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Proliferation; Cell Survival; Drug Synergism; Gene Silencing; HL-60 Cells; Humans; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Oligonucleotides, Antisense; Oxides; Primary Cell Culture; Transfection; Trypan Blue; Vascular Endothelial Growth Factor A

2012
Downregulation of Mcl-1 through GSK-3β activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells.
    Leukemia, 2013, Volume: 27, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Down-Regulation; Enzyme Activation; Flow Cytometry; Glutathione; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Leukemia, Myeloid, Acute; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Oxides; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; RNA, Small Interfering; Tumor Cells, Cultured

2013
Synergism between carnosic acid and arsenic trioxide on induction of acute myeloid leukemia cell apoptosis is associated with modulation of PTEN/Akt signaling pathway.
    Chinese journal of integrative medicine, 2012, Volume: 18, Issue:12

    Topics: Abietanes; Apoptosis; Arsenic Trioxide; Arsenicals; Base Sequence; Blotting, Western; Cell Cycle; DNA Primers; Drug Synergism; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Oxides; Plant Extracts; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction

2012
A case report of acute myeloid leukemia after liver transplantation.
    Acta haematologica, 2013, Volume: 129, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow; Cytarabine; Daunorubicin; Hepatitis B; Humans; Leukemia, Myeloid, Acute; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Mitoxantrone; Oxides; Tretinoin

2013
Regulation of the kinase RSK1 by arsenic trioxide and generation of antileukemic responses.
    Cancer biology & therapy, 2013, Volume: 14, Issue:5

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Electrophoresis, Polyacrylamide Gel; Humans; Leukemia, Myeloid, Acute; MAP Kinase Signaling System; Oxides; Phosphorylation; Ribosomal Protein S6 Kinases, 90-kDa; U937 Cells

2013
A case of M2a with complex chromosome aberrations obtained complete remission through modified As2O3 medication.
    Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih, 2004, Volume: 19, Issue:2

    Topics: Adult; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Chromosome Aberrations; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Oxides; Remission Induction

2004
L-ascorbic acid represses constitutive activation of NF-kappaB and COX-2 expression in human acute myeloid leukemia, HL-60.
    Journal of cellular biochemistry, 2004, Oct-01, Volume: 93, Issue:2

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Cyclooxygenase 2; DNA; Down-Regulation; Electrophoretic Mobility Shift Assay; Glutathione; HL-60 Cells; Humans; Hydrogen Peroxide; Isoenzymes; Leukemia, Myeloid, Acute; Membrane Proteins; NF-kappa B; Oxides; Prostaglandin-Endoperoxide Synthases; Protein Subunits; Superoxides; Tosylphenylalanyl Chloromethyl Ketone; Transcription Factor RelA

2004
Arsenic trioxide represses constitutive activation of NF-kappaB and COX-2 expression in human acute myeloid leukemia, HL-60.
    Journal of cellular biochemistry, 2005, Mar-01, Volume: 94, Issue:4

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cyclooxygenase 2; DNA; Enzyme Activation; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glutathione; HL-60 Cells; Humans; Hydrogen Peroxide; I-kappa B Kinase; Leukemia, Myeloid, Acute; Membrane Proteins; NF-kappa B; Oxides; Prostaglandin-Endoperoxide Synthases; Protein Binding; Protein Serine-Threonine Kinases; Protein Subunits; Protein Transport

2005
Biological effects of Atra and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts.
    Leukemia & lymphoma, 2005, Volume: 46, Issue:2

    Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Bromodeoxyuridine; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Drug Interactions; Humans; Ki-67 Antigen; Kinetics; Leukemia, Myeloid, Acute; Oxides; S Phase; Tretinoin; Tumor Cells, Cultured

2005
MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis.
    Blood, 2006, Jun-01, Volume: 107, Issue:11

    Topics: Adult; Aged; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Female; Genes, Tumor Suppressor; Humans; Leukemia, Myeloid, Acute; Male; MAP Kinase Kinase 1; Middle Aged; Nuclear Proteins; Oxides; Tumor Cells, Cultured; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins

2006
Arsenic trioxide affects signal transducer and activator of transcription proteins through alteration of protein tyrosine kinase phosphorylation.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Nov-15, Volume: 12, Issue:22

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Carrier Proteins; Cell Cycle; Cell Proliferation; DNA-Binding Proteins; Humans; Leukemia, Myeloid, Acute; Oxides; Phosphorylation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Signal Transduction; STAT Transcription Factors; STAT3 Transcription Factor; Transcription Factors; Transfection; Tumor Cells, Cultured

2006
[Correlation between expression of apoptosis-related gene pnas-2 and leukemia].
    Zhongguo shi yan xue ye xue za zhi, 2007, Volume: 15, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Arsenicals; Female; Humans; K562 Cells; Leukemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Sulfides; Tumor Cells, Cultured; U937 Cells; Young Adult

2007
Regulatory effects of mammalian target of rapamycin-mediated signals in the generation of arsenic trioxide responses.
    The Journal of biological chemistry, 2008, Jan-25, Volume: 283, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Eukaryotic Initiation Factors; Gene Deletion; Humans; K562 Cells; Leukemia, Myeloid, Acute; Neoplastic Stem Cells; Oxides; Protein Kinases; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins; U937 Cells

2008
[Occupational exposure and malignant hemopathies: a case-control study in Lyon (France)].
    Revue d'epidemiologie et de sante publique, 1995, Volume: 43, Issue:3

    Topics: Adult; Aged; Alkalies; Arsenicals; Case-Control Studies; Dose-Response Relationship, Drug; Dust; Female; Humans; Ink; Leukemia; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mineral Oil; Occupational Exposure; Odds Ratio

1995
Effects of arsenic trioxide (As2O3) on leukemic cells from patients with non-M3 acute myelogenous leukemia: studies of cytotoxicity, apoptosis and the pattern of resistance.
    European journal of haematology, 2001, Volume: 66, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporter, Subfamily B; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance; Drug Resistance, Multiple; Female; HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid, Acute; Male; Middle Aged; Oxides; Transfection; Tumor Cells, Cultured

2001
Comparing Arsenic-Containing Qinghuang Powder and Low-Intensity Chemotherapy in Elderly Patients with Acute Myeloid Leukemia.
    Chinese journal of integrative medicine, 2023, Volume: 29, Issue:9

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic; Humans; Leukemia, Myeloid, Acute; Powders; Prognosis; Retrospective Studies

2023
Venetoclax and arsenic showed synergistic anti-leukemia activity in vitro and in vivo for acute myeloid leukemia with the NPM1 mutation.
    American journal of hematology, 2020, Volume: 95, Issue:3

    Topics: Arsenic; Bridged Bicyclo Compounds, Heterocyclic; Cell Line; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Mutation; Neoplasm Proteins; Nuclear Proteins; Nucleophosmin; Sulfonamides

2020
[Arsenic: The gold standard for acute promyelocytic leukaemia with FLT3-ITD mutation].
    Medecine sciences : M/S, 2021, Volume: 37, Issue:5

    Topics: Antineoplastic Agents; Arsenic; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Mutation

2021
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, May-10, Volume: 35, Issue:14

    Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Cyclosporine; Cytarabine; Decitabine; Disease Progression; Enzyme Inhibitors; Erythrocyte Transfusion; Female; Hematinics; Humans; Hydroxyurea; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide; Treatment Failure; Tretinoin; Valproic Acid

2017
Arsenic and old
    Blood, 2019, 03-28, Volume: 133, Issue:13

    Topics: Animals; Arsenic; fms-Like Tyrosine Kinase 3; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Mice; Tretinoin

2019
Risk of leukemia in relation to exposure to ambient air toxics in pregnancy and early childhood.
    International journal of hygiene and environmental health, 2014, Volume: 217, Issue:6

    Topics: Air Pollutants; Arsenic; Butadienes; California; Case-Control Studies; Child, Preschool; Chloroform; Environmental Exposure; Female; Humans; Hydrocarbons, Cyclic; Infant; Leukemia, Myeloid, Acute; Logistic Models; Maternal Exposure; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pregnancy; Risk Factors; Selenium; Vehicle Emissions

2014
Leukemia in arsenic poisoning.
    Annals of internal medicine, 1972, Volume: 77, Issue:6

    Topics: Aged; Anemia, Aplastic; Arsenic; Arsenic Poisoning; Autopsy; Biopsy; Bone Marrow Cells; Cytarabine; Environmental Exposure; Humans; Klebsiella Infections; Leukemia, Myeloid, Acute; Male; Oxymetholone; Penicillamine; Pesticides; Poisoning; Prednisone; Recurrence; Sepsis; Thioguanine

1972